FDA DRAFT Guidance - Basic Safety and Essential Performance of Medical Electrical Equipment - Standards For Accreditation Scheme
FDA DRAFT Guidance - Basic Safety and Essential Performance of Medical Electrical Equipment - Standards For Accreditation Scheme
You should submit comments and suggestions regarding this draft document within 60 days of
publication in the Federal Register of the notice announcing the availability of the draft
guidance. Submit electronic comments to https://www.regulations.gov. Submit written
comments to the Dockets Management Staff, Food and Drug Administration, 5630 Fishers Lane,
Room 1061, (HFA-305), Rockville, MD 20852. Identify all comments with the docket number
listed in the notice of availability that publishes in the Federal Register.
For questions about this document, For questions about this document regarding CDRH-regulated
devices, contact the ASCA Program at [email protected]. For questions about this document
regarding CBER-regulated devices, contact the Office of Communication, Outreach, and
Contains Nonbinding Recommendations
When final, this guidance will supersede Basic Safety and Essential
Performance of Medical Electrical Equipment, Medical Electrical Systems,
and Laboratory Medical Equipment – Standards Specific Information for the
Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program,
issued September 25, 2020.
ii
Contains Nonbinding Recommendations
Preface
Additional Copies
CDRH
Additional copies are available from the Internet. You may also send an e-mail request to
[email protected] to receive a copy of the guidance. Please include the document
number 20001 and complete title of the guidance in the request.
CBER
Additional copies are available from the Center for Biologics Evaluation and Research (CBER),
Office of Communication, Outreach, and Development (OCOD), 10903 New Hampshire Ave.,
Bldg. 71, Room 3128, Silver Spring, MD 20993-0002, or by calling 1-800-835-4709 or 240-402-
8010, by email, [email protected], or from the Internet at https://www.fda.gov/vaccines-blood-
biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances.
iii
Contains Nonbinding Recommendations
iv
Contains Nonbinding Recommendations
21 I. Introduction
22 This guidance provides information regarding how basic safety and essential performance
23 standards are incorporated into the Accreditation Scheme for Conformity Assessment
24 Program (hereafter referred to as the ASCA Program). The ASCA Program is described in
25 FDA’s guidance on The Accreditation Scheme for Conformity Assessment (ASCA)
26 Program.
27
Contains Nonbinding Recommendations
28 For the edition of FDA-recognized consensus standard(s) included in the ASCA Program,
29 see the FDA Recognized Consensus Standards Database. For more information regarding use
30 of FDA-recognized consensus standards in regulatory submissions, please refer to FDA’s
31 guidances entitled Appropriate Use of Voluntary Consensus Standards in Premarket
32 Submissions for Medical Devices, Safety and Performance Based Pathway, and Standards
33 Development and the Use of Standards in Regulatory Submissions Reviewed in the Center
34 for Biologics Evaluation and Research.
35
36 FDA’s guidance documents, including this guidance, do not establish legally enforceable
37 responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and
38 should be viewed only as recommendations, unless specific regulatory or statutory
39 requirements are cited. The use of the word should in Agency guidance means that
40 something is suggested or recommended, but not required.
41 II. Scope
42 This guidance includes the following:
43
44 • the ASCA Program specifications for the FDA-recognized consensus standards and
45 test methods for basic safety and essential performance;
46 • assessment and accreditation of Testing Laboratories by ASCA-recognized
47 Accreditation Bodies; and
48 • the recommended premarket submission contents specific to FDA-recognized
49 consensus standards and test methods for basic safety and essential performance
50 when testing is conducted by an ASCA-accredited testing laboratory.
51
52 FDA guidance The Accreditation Scheme for Conformity Assessment (ASCA) Program
53 describes how accreditation bodies, testing laboratories, device manufacturers, and FDA staff
54 participate in the ASCA Program as well as how FDA-recognized consensus standards and
55 test methods are selected and how Program specifications are developed.
56
2
Contains Nonbinding Recommendations
1
In this document, the reference to the IEC 60601/80601 series of standards includes the ANSI/AAMI ES
60601-1, the IEC and US adopted collaterals [6060-1-xx], the IEC 60601-2-xx particulars, and the IEC or ISO
80601-2-xx particulars.
2
See 7.9.3 of ISO/IEC 17011: 2017: Conformity assessment – Requirements for accreditation bodies
accrediting conformity assessment bodies.
3
Contains Nonbinding Recommendations
92 the end of the accreditation cycle that confirms the competence of each testing laboratory for
93 all the requirements of the consensus standards within the laboratory’s scope of
94 accreditation. 3 There are no additional expectations for assessments under the ASCA
95 Program for basic safety and essential performance standards. That is, in the ASCA Program,
96 ASCA-recognized accreditation bodies may assess a sample of the basic safety and essential
97 performance standards to ensure competence across the testing laboratory’s entire scope of
98 ASCA Accreditation.
99 B. ASCA Program Specifications for Basic Safety and
100 Essential Performance of Medical Electrical Equipment,
101 Medical Electrical Systems, and Laboratory Medical
102 Equipment
103 The ASCA Program specifications in this section provide expectations for the accreditation
104 of testing laboratories for basic safety and essential performance of medical electrical
105 equipment, medical electrical systems, and laboratory medical equipment under the ASCA
106 Program. ASCA-recognized accreditation bodies, following the processes of ISO/IEC
107 17011, accredit testing laboratories to ISO/IEC 17025:2017: General requirements for the
108 competence of testing and calibration laboratories (hereafter referred to as “ISO/IEC
109 17025”) as well as to the ASCA Program specifications identified in this section.Throughout
110 the ASCA Program specifications below, the term “will” before each action for testing
111 laboratories is used to convey that they they are able to provide supportive documentation or
112 information demonstrating competence to each of the ASCA Program specifications below
113 when undergoing assessments by ASCA -recognized accrediting bodies. ASCA-recognized
114 accreditation bodies will assess the laboratories to the specifications to ensure ASCA
115 Program specifications are met.
116
117 In addition, all testing should be conducted considering the recommendations of relevant
118 FDA guidance documents (refer to Section III. of this guidance). For readability and ease of
119 reference, the numbering and nomenclature (including the term “requirements”) 4 below
120 correspond to the numbering and nomenclature of clauses/subclauses in ISO/IEC 17025.
3
See 7.9.4 of ISO/IEC 17011: 2017: Conformity assessment – Requirements for accreditation bodies
accrediting conformity assessment bodies.
4
Some definitions within FDA-recognized consensus standards refer to ‘requirements.’ FDA’s references to
them for the ASCA Program do not make them legal or regulatory requirements unless specifically identified as
such.
4
Contains Nonbinding Recommendations
129 records (i.e., the risk management file), the testing laboratory is to check to see if a related
130 IEC 60601/80601 or IEC 61010 expectation has been complied with.
132 If any services, such as consulting, design, or research, are offered by the testing laboratory,
133 it will have a policy and procedure for maintaining impartiality through separation of those
134 services from its testing activities.
135
136 A device manufacturer’s internal testing laboratory will have policies and procedures that
137 specifically ensure and protect the impartiality of the laboratory to test or otherwise evaluate
138 devices manufactured by the laboratory’s parent organization and, if applicable, other device
139 manufacturers without regard to the impact of the test results on the parent organization’s
140 business interests.
152 a) The testing laboratory will maintain technical personnel who are qualified and
153 competent to:
154 • Establish and perform the appropriate test methods required for the standard.
155 • Understand and apply the specifications and underlying rationale (including such
156 concepts as basic safety and essential performance).
157 • Understand other normative references in the relevant standards forming part of
158 the requested scope of accreditation.
159 • Assure the suitability of means used to confirm the basic safety and essential
160 performance of the medical device under test.
5
Contains Nonbinding Recommendations
165 • Provide ongoing training of technical personnel at specified intervals or when test
166 standards or methods are updated or developed, as well as when responsibilities
167 have changed.
168 • Conduct training through appropriate training mechanisms, such as on-the-job
169 training or formal classroom training.
170 • Document and maintain records of training for technical personnel.
171 c) The testing laboratory will maintain job descriptions that specify and document the
172 responsibilities and required competencies of managerial, technical, and key support
173 personnel involved in requested scope of accreditation.
178 a) The testing laboratory will ensure that all equipment used for testing and evaluating
179 devices is available and in proper working order for the requested scope of
180 accreditation.
181 b) The testing laboratory will ensure that its procedures specify the steps for establishing
182 calibration intervals for each type or item of equipment, and specify criteria, steps,
183 and approvals for extending the calibration interval of an instrument.
184 c) The testing laboratory will ensure that its procedures address adding, deleting,
185 modifying, or maintaining information in equipment records in an accurate and timely
186 manner, and specify the personnel responsible for these tasks.
187 d) The testing laboratory will have procedures to examine the effects of defective or out-
188 of-tolerance equipment on calibrations and tests. The testing laboratory further agrees
189 that procedures will identify the personnel responsible for such examinations, specify
190 their responsibilities, and provide the steps for the examination, including:
191 • Determining whether the effects are unacceptable (including the accept/reject
192 criteria);
193 • Identifying the devices affected;
194 • Analyzing the particular tests impacted for these devices; and determining
195 whether retesting is required;
196 • Preparing a report of the examination;
197 • Notifying customers when retesting is required; and
198 • Specifying the steps to follow to perform the retesting.
6
Contains Nonbinding Recommendations
217 a) The testing laboratory agrees that its management system will include procedures
218 governing the development, maintenance, and use of test procedures (including
219 associated records in paper or electronic format such as test data forms and
220 checklists). The testing laboratory further agrees that these management system
221 procedures will include steps for:
222 • Ensuring that test procedures are documented and reviewed prior to use;
223 • Identifying the personnel responsible for developing, reviewing, and maintaining
224 test procedures;
225 • Ensuring that new and revised test procedures are reviewed by personnel who are
226 competent and trained in the applicable standard(s); and
227 • Specifying the criteria for review.
228 b) The testing laboratory agrees that test procedures and project-specific test plans will
229 include or specify, as appropriate, the following information:
230 • Unique identification of the test procedure or plan, including title, document
231 number, revision, and effective date;
232 • Specific test equipment to use or the salient performance characteristics required
233 of the equipment to be used;
234 • Warnings/caution statements to alert the operators of potential hazards;
235 • Normal and any unusual ambient conditions (including tolerances) for tests;
236 • Test data to be obtained and recorded;
237 • Objective acceptance criteria for results including the essential performance
238 required to be maintained;
239 • Testing techniques required to ensure consistent results;
240 • Instructions on equipment operation and on handling and preparation of test
241 samples (including instructions on multiple sample marking, if applicable); and
7
Contains Nonbinding Recommendations
242 • The methods to be used to assess or monitor the performance of the test sample.
243 c) The testing laboratory will ensure that relevant contextual information from the
244 intended use of the device’s essential performance specifications, including any
245 metrological stability, are reflected in the relevant test procedure or project-specific
246 test plan.
247 d) The testing laboratory will ensure that each test procedure adequately addresses all
248 the applicable requirements of the standard for the equipment under test.
249 e) The testing laboratory will give preference to using test methods in the requested
250 scope of accreditation. Modified test methods as permitted by IEC 60601-1
251 subclauses 4.2.3.2 and 4.5 and ISO/IEC 17025 subclause 7.2.1.4 may be used within
252 the ASCA Program as long as details of the rationale for the modification, test
253 method, and results are provided.
254 Note: Recommendations for how to report the modified test method can be found in
255 FDA’s guidance Recommended Content and Format of Non-Clinical Bench
256 Performance Testing Information in Premarket Submissions.
257 f) The testing laboratory will include relevant sections of the test report in the ASCA
258 Summary Test Report as necessary to explain any testing to address risks that are
259 different or in addition to those found in the FDA-recognized consensus standard.
8
Contains Nonbinding Recommendations
281 a) The testing laboratory will have procedures to record and report all required
282 information in ISO/IEC 17025 for each test conducted, including the following:
283 • A statement of the extent to which the articles that were tested complied or did
284 not comply with the specifications of each clause or subclause that were part of
285 the standard tested;
286 • A detailed description of the medical device tested including accessories, options,
287 software versions, and configurations tested;
288 • A test plan including reference to the device manufacturer’s stated intended use
289 and essential performance claims monitored during testing, any additional device-
290 specific acceptance criteria (beyond those detailed in specific consensus
291 standards) monitored during testing, reporting of the operational state(s) of the
292 equipment during each test, as well as, if needed, any modified test methods as
293 permitted by IEC 60601-1 subclauses 4.2.3.2 and 4.5 and ISO/IEC 17025
294 subclause 7.2.1.4.
295
296 Note: Recommendations for how to report the modified test methods can be found
297 in the guidance document Recommended Content and Format of Non-Clinical
298 Bench Performance Testing Information in Premarket Submissions.
299
300 • The date and location of the test(s) performed;
301 • The test report’s unique identifier;
302 • The signatures and printed names of the personnel responsible for the test results;
303 • The test conditions, e.g., supply voltage, ambient temperature or humidity, when
304 relevant to the test;
305 • All of the applicable data required for equipment under test according to the
306 standard;
307 • A statement of the estimated uncertainty of measurement, when it is relevant to
308 the validity or application of the test results, when a customer’s instructions so
309 requires or when the uncertainty affects compliance to a specification limit; and
310 • A statement that test report meets ASCA Program specifications.
311
312 b) The testing laboratory agrees not to report test results in a “simplified way” as
313 mentioned in subclause 7.8.1.3. Instead, the testing laboratory will report to the
314 customer all information listed in subclauses 7.8.2 through 7.8.7 to the extent
315 applicable (Subclause 7.8.4 is for calibration certificates and is not applicable when
316 testing to the requirements of IEC 60601).
317
9
Contains Nonbinding Recommendations
318 c) The testing laboratory will convey to the customer, in writing, all opinions and
319 interpretations, including concerns about basic safety and essential performance such
320 as:
321 • Anomalous test results noted during any part of the testing that were not resolved
322 to the testing laboratory’s satisfaction; and
323 • Concerns regarding any other aspect of conformity to the standard.
324 d) The testing laboratory will require that testing conducted by subcontractors will also
325 comply with the above test report specifications, as applicable.
326 e) The testing laboratory agrees that an ASCA Summary Test Report including the
327 content specified in this guidance will be submitted to the customer at the end of
328 testing activities.
329 f) The testing laboratory will convey to the customer, in writing, all observations
330 recorded during execution of a project test plan.
331
332 Note. An observation is a device behavior that is not directly related to the pass/fail
333 assessment being made at that time. An observation is recorded to make the customer
334 aware of a device behavior that, while it might be out-of-scope for the test plan being
335 executed, could indicate a potential quality issue. It is the customer’s responsibility to
336 assess this further.
10
Contains Nonbinding Recommendations
11
Contains Nonbinding Recommendations
396 If the testing laboratory has questions or concerns associated with the device manufacturer’s
397 proposed test plan (e.g., essential performance(s), unclear acceptance criteria), they should
398 discuss such concerns/questions with the device manufacturer, preferentially in advance of
399 finalization of the test plan. If those concerns or questions remain unresolved, the testing
400 laboratory should consider detailing the potential issues in the ASCA Summary Test Report
401 (e.g., in the Concerns Identified section in the example provided in Appendix B of this
402 guidance).
403 (1) Essential Performance
404 FDA recommends the device manufacturer specifies the essential performance(s) of their
405 device. Additionally, testing laboratories should have expertise in the terminology,
406 evaluation, and performance of the FDA-recognized consensus standards to assist a device
407 manufacturer in understanding the concept of essential performance and how it might relate
408 to their device, as appropriate.
409
410 We recommend that testing laboratories and device manufacturers consider the content of the
411 AAMI consensus report CR500:2019, Basic Introduction to the IEC 60601 Series, which
412 includes clarifications to help device manufacturers understand “essential performance.” 5
413
414 If a device manufacturer is unsure what constitutes the essential performance(s) of their
415 device, FDA recommends submitting a Q-submission 6 prior to initiating testing to request
416 formal feedback from the appropriate CDRH Office of Health Technology (OHT) or CBER
417 Review Office for their future premarket submission. For information on presubmissions,
418 please see the FDA guidance entitled “Requests for Feedback and Meetings for Medical
419 Device Submissions: The Q-Submission Program.”
420 (2) Electromagnetic Compatibility (EMC)
421 For test plans that intend to use the current, FDA-recognized version of the IEC 60601-1-2
422 collateral standard, we recommend that device manufacturers and testing laboratories
423 consider the FDA guidance entitled “Electromagnetic Compatibility (EMC) of Medical
424 Devices.” This guidance provides recommendations that might impact test plans including
425 current, FDA-recognized versions of IEC 60601-1-2.
426
427
5
For additional information about a regulatory perspective on “essential performance,” we recommend the
AAMI consensus report entitled CR500:2019 Basic Introduction to the IEC 60601 Series.
6
For more information, please see the FDA guidance entitled “Requests for Feedback and Meetings for
Medical Device Submissions: The Q-Submission Program.”
12
Contains Nonbinding Recommendations
13
Contains Nonbinding Recommendations
7
For more information, please see the FDA guidance entitled “Electromagnetic Compatibility (EMC) of
Medical Devices” (https://www.fda.gov/regulatory-information/search-fda-guidance-
documents/electromagnetic-compatibility-emc-medical-devices) and IEC TR 60601-4-2.
14
Contains Nonbinding Recommendations
502 suspended from the scope of ASCA Accreditation at the time testing was conducted. If
503 the relevant standard was impacted by a suspension of ASCA Accreditation, the
504 ASCA DOC should include an explanation of how this suspension may or may not
505 affect the testing results.
506 • Limitations on the validity of the ASCA DOC:
507 • How the test article compares with the device provided in the premarket
508 submission, including any modifications made during testing. If modifications
509 were made during testing, it is helpful if the ASCA DOC states whether or not
510 these modifications are included in the final finished device. FDA also
511 recommends that the ASCA DOC include a rationale for why it was deemed
512 appropriate to leverage any testing conducted before the modifications were
513 made.
514 • Details about how any concerns communicated by the test laboratory have been
515 mitigated (see Section V.C.1. above).
516 • Details about how any observations and/or degradations during testing were
517 resolved.
518 • If there is additional data or documentation that support any of the limitations on
519 the validity of the ASCA DOC, FDA recommends that a reference identifying
520 where to find this information be provided in the ASCA DOC.
8
An ASCA Summary Test Report is different from the test report summary described in FDA’s guidance
Recommended Content and Format of Non-Clinical Bench Performance Testing Information in Premarket
Submissions.
15
Contains Nonbinding Recommendations
539 modifications or additions to individual clauses or subclauses to ensure basic safety and
540 essential performance, FDA recommends the submitter include the test plan and procedure,
541 acceptance criteria, and results justifying the safety claim in its premarket submission. In
542 such cases, FDA recommends that the ASCA Summary Test Report include relevant
543 information about the testing that was performed. The following examples illustrate a few
544 situations where this additional documentation is appropriate:
545
546 • Where a test method specified in a clause or subclause of the standard was modified
547 based on specific characteristics and/or intended use of the device or its operating
548 conditions.
549 • Where the acceptance criteria specified in a clause or subclause was modified based
550 on the device manufacturer’s risk management.
551 • Where clauses or subclauses in the IEC 60601/80601 and IEC 61010 series do not
552 provide specific test methods and acceptance criteria. For example, a clause or
553 subclause might indicate “compliance is checked by inspection of the risk
554 management file and functional tests, if necessary.” In other cases, a clause or
555 subclause might provide for revision of the specific test methods and acceptance
556 criteria based on risk management.
16
Contains Nonbinding Recommendations
9
Rounded to the nearest whole number.
17
Contains Nonbinding Recommendations
All identifying information for the product/device (e.g., product code(s), device marketing
name(s), model number(s), etc.).
589
590 Statement of Conformity
591 The test results demonstrate that the device is in conformity with the standard(s) listed
592 below 11:
593 • Title of Standard(s): 12 (e.g., ANSI/AAMI ES60601-1 Medical electrical equipment
594 - Part 1: General requirements for basic safety and essential
595 performance.)______
596 • FDA Recognition #(s): (e.g., 19-46)
597 • Options Selected
598 Standard(s) included no options
599 Standard(s) included options
10
Available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/appropriate-use-
voluntary-consensus-standards-premarket-submissions-medical-devices
11
See section 514(c)(3)(A)(i) of the FD&C Act, cited in Section IV.A.(3)(f) of FDA’s guidance Appropriate
Use of Voluntary Consensus Standards in Premarket Submissions for Medical Device.
12
A device manufacturer may declare conformity to multiple standards evaluated by a test lab within the ASCA
Program.
18
Contains Nonbinding Recommendations
602 • Testing Location(s): (e.g., 1234 Example Road, Silver Spring, MD 20993)
603 • Testing Date(s): (e.g., Sep 1, 2023 – Sep 15, 2023)
604 • ASCA Accreditation Status on the Date(s) of Testing:
605 Standard was not in testing laboratory’s scope of ASCA Accreditation
606 Standard was in testing laboratory’s scope of ASCA Accreditation;
607 ASCA Accreditation was not suspended
608 ASCA Accreditation was suspended
609 • Supplemental Documentation (Refer to Section VI.C. of this guidance for specific
610 recommendations):
611 Supplemental documentation is not included
612 Supplemental documentation is included at the following location within the
613 submission, and I have checked that there are no differences regarding
614 protocol and data between the testing conducted and the supplemental
615 documentation: (e.g., IEC 60601-1-2 ASCA Summary Test Report located in
616 Appendix A of this premarket submission)__________
617
618
19
Contains Nonbinding Recommendations
Description of any limitation on the validity of the ASCA DOC (e.g., how long the declaration is
valid, what was tested, or concessions made about the testing outcomes) including a reference to
the relevant locations of such information in the premarket submission. For testing from an
ASCA-accredited test lab, this should include:
• Information on how the test article compares with the device provided in this
premarket submission including, any modifications made during testing for basic
safety and essential performance and whether the modifications are included in the
final, finished device.
• Information on how any concerns communicated by the test laboratory were
resolved.
• Information on how any observations and/or degradations during testing were
resolved.
• Information about how conformity was assessed for clauses or subclauses of the
relevant standard(s) that were not evaluated by an ASCA-accredited testing
laboratory, including detailed information about who performed such testing, the test
methods used, and the test results
• Information on how the labeling requirements of the standard are met (e.g.,
reference to relevant section/pages of the user manual).
621
622
623 Signature
624 Printed name: _______________________________________________________________
625 Function within entity responsible for DOC: _______________________________________
626
627 ___________________________________________________________________________
628 Signature Date
629
630
20
Contains Nonbinding Recommendations
13
See FDA’s guidance Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for
Medical Devices for information regarding supplemental documentation necessary to support FDA-recognized
consensus standards that are not in a testing laboratory’s scope of ASCA Accreditation.
21
Contains Nonbinding Recommendations
Pass/Fail criteria specific to the device should be clear and verifiable. Pass/Fail criteria
might include device-specific criteria for clinical functions unrelated to identified essential
performance.
658
659 Use Environment
660 Home Healthcare Environment [IEC 60601-1-11]
661 Professional Healthcare Facility Environment
662 Magnetic Resonance (MR) Environment
663 Commercial Aircraft Environment
664 Emergency Medical Services Environment [IEC 60601-1-12]
665 Special / Other Environment
666
Include any relevant details regarding the specified use environment here.
List of all clauses and subclauses identified as not applicable (N/A) with a rationale for
every clause/subclause identified as N/A. This may be provided as an attachment to the
Summary Test Report.
22
Contains Nonbinding Recommendations
List of any applicable clauses or subclauses not tested. Rationales should also be provided
to clarify why applicable clauses/subclauses were not tested.
If specific clauses or subclauses are determined to be applicable but are not within the
testing laboratory’s scope of accreditation (i.e., excluded in the scope of accreditation),
then those clauses/subclauses should be listed here with a corresponding explanation.
677
678 3. Clauses/Subclauses with Failing Results
679 No clauses or subclauses had failing results
680 The following clauses/subclauses had failing results
List of any clauses and subclauses with failing results and a description of the failures.
List of test methods and/or acceptance criteria that were modified. Appropriate supporting
documents should be attached to this ASCA Summary Test Report including the rationale for
the modification, test plan and procedure, acceptance criteria that were applied, scientific
rationale for the acceptance criteria, and the test results.
14
Modification(s) include special test conditions and additions or modifications to test methods and/or
acceptance criteria as permitted by IEC 60601-1 subclauses 4.2.3.2 and 4.5 and ISO/IEC 17025 subclause
7.2.1.4.
15
For example, subclause 4.2 of ANSI/AAMI ES60601 indicates that hazards not specifically addressed in the
ANSI/AAMI ES60601-1 are to be addressed in the risk management process.
23
Contains Nonbinding Recommendations
Description of how device was configured including modes of operation used during testing.
Description of observations and degradations of concern to the testing laboratory but deemed
acceptable. Examples include:
This list should capture any unexpected events. As an example, an error message would be
unexpected (and therefore would be listed) during EMC testing when a valid input is present;
conversely, the same error message would be expected (and therefore would not be listed)
during a test that feeds an out-of-range input to verify the function of input errors. Any
unexpected behavior is reported even if acceptable per the pass/fail criteria. If the unexpected
behavior is listed as possible in the labeling (e.g., “the device may restart unexpectedly”), it
should still be reported here.
696
697 Modifications to Test Article(s) During Testing
698 No modifications were made to the test articles during testing
699 Modifications were made to the test articles during testing. Description of modification
700 including their impact on prior test outcome(s) are provided below.
Description of modifications made to test articles during testing. Description of prior tests that
were repeated based on modifications made or justification for not repeating prior tests.
24
Contains Nonbinding Recommendations
Concerns may include aspects that do not constitute a failure for the specific test conducted,
but might have an impact on the safety and potential effectiveness of the device subject to the
testing. Examples include, but are not limited to, concerns regarding the test plan (e.g., unclear
pass/fail criteria or essential performance(s), disagreements regarding the evaluation of
certain clauses or subclauses), inconsistencies in risk analysis (e.g., underestimation of risk
level, unidentified risks related to the device) based on the test laboratory’s experience with
specific device types, presence of unique features/characteristics which may raise safety
questions not addressed via the test plan.
704
705 I confirm that:
706 The above summary information includes all original and any retest data
707 The above summary information is an accurate representation of the testing conducted
708
709
710
711 __________________________________________________________________________
712 Name: [TYPED NAME POSITION] Date
713
25